GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Wockhardt Ltd (BOM:532300) » Definitions » EV-to-EBITDA

Wockhardt (BOM:532300) EV-to-EBITDA : 128.19 (As of May. 03, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Wockhardt EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Wockhardt's enterprise value is ₹108,960 Mil. Wockhardt's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was ₹850 Mil. Therefore, Wockhardt's EV-to-EBITDA for today is 128.19.

The historical rank and industry rank for Wockhardt's EV-to-EBITDA or its related term are showing as below:

BOM:532300' s EV-to-EBITDA Range Over the Past 10 Years
Min: -374.46   Med: 16.41   Max: 948.07
Current: 128.18

During the past 13 years, the highest EV-to-EBITDA of Wockhardt was 948.07. The lowest was -374.46. And the median was 16.41.

BOM:532300's EV-to-EBITDA is ranked worse than
96.74% of 706 companies
in the Drug Manufacturers industry
Industry Median: 14.54 vs BOM:532300: 128.18

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-03), Wockhardt's stock price is ₹569.55. Wockhardt's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₹-34.770. Therefore, Wockhardt's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Wockhardt EV-to-EBITDA Historical Data

The historical data trend for Wockhardt's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wockhardt EV-to-EBITDA Chart

Wockhardt Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -404.80 36.63 -93.81 50.69 -56.34

Wockhardt Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.02 -56.34 -31.72 69.71 71.86

Competitive Comparison of Wockhardt's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Wockhardt's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Wockhardt's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Wockhardt's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Wockhardt's EV-to-EBITDA falls into.



Wockhardt EV-to-EBITDA Calculation

Wockhardt's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=108959.503/850
=128.19

Wockhardt's current Enterprise Value is ₹108,960 Mil.
Wockhardt's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹850 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Wockhardt  (BOM:532300) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Wockhardt's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=569.55/-34.770
=At Loss

Wockhardt's share price for today is ₹569.55.
Wockhardt's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-34.770.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Wockhardt EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Wockhardt's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Wockhardt (BOM:532300) Business Description

Traded in Other Exchanges
Address
Wockhardt Towers, Bandra-Kurla Complex, Bandra (East), Mumbai, MH, IND, 400 051
Wockhardt Ltd is a major drug manufacturing company with a focus on pharmaceutical and biotechnology products. The company conducts research in the fields of pharmaceuticals and biotechnology while also operating its chain of Super Specialty Hospitals. The vast majority of the company's revenue is generated in Europe. The company also operates in China, Japan, and Russia. The company's strategy includes the use of acquisitions, strategic partnerships, and contract manufacturing.

Wockhardt (BOM:532300) Headlines

No Headlines